Bal Pharma Reports Q1 FY2026 Results, Approves Employee Stock Option Plan
Bal Pharma Limited released its Q1 FY2026 financial results. Standalone revenue from operations was ₹6563.51 lakhs with a net profit of ₹32.31 lakhs. Consolidated revenue stood at ₹6587.09 lakhs with a net profit of ₹20.85 lakhs. The company announced its 38th AGM for September 25, 2025, to be held virtually. Book closure dates are set from September 19 to 25, 2025. The Board approved an Employee Stock Option Plan-2025, subject to shareholder approval. Auditors provided an unmodified opinion on the financial results. The company continues to operate in the 'Pharmaceuticals' segment.
29Jul 25
Bal Pharma Schedules Board Meeting to Discuss Q1 Results, ESOP, and Subsidiary Merger
Bal Pharma has scheduled a Board of Directors meeting for August 11, 2025, with a comprehensive agenda. Key items include reviewing Q1 financial results, planning the 38th AGM, considering an Employee Stock Option Plan-2025, and potentially merging subsidiary Lifezen Healthcare Pvt Ltd. A trading window closure is in effect from June 1 to August 14, 2025, for designated persons and employees.